Dermatology Continuing Medical Education

Episodes 1-15 of 26

• 

  RestartResume

  Getting to the Root of CKD-Associated Pruritus: Questions From the Field

  CME/CE

  Getting to the Root of CKD-Associated Pruritus: Questions From the Field

  • 

    

    Joel Topf, MD

    Peer

  • 

    

    James Burton, MD

    Peer

  0.25 credits

• 

  RestartResume

  Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma

  CME/CE

  Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma

  • 

    

    Meghan Mooradian, MD

    Peer

  0.25 credits

• 

  RestartResume

  Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP

  CME/CE

  Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP

  • 

    

    Jay Reddy, MD, FASN

    Peer

  • 

    

    Carlos Narváez Mejía, MD

    Peer

  0.25 credits

• 

  RestartResume

  Understanding the Recent Advances in IgAN

  CME/CE

  Understanding the Recent Advances in IgAN

  • 

    

    Jürgen Floege, MD

    Peer

  • 

    

    Jonathan Barratt, PhD

    Peer

  0.25 credits

• 

  RestartResume

  I Just Need to Sleep! Improving Itch in Patients With CKD-aP

  CME/CE

  I Just Need to Sleep! Improving Itch in Patients With CKD-aP

  • 

    

    Kieran McCafferty, MD

    Peer

  • 

    

    Prof. Dr. Jörg Latus

    Peer

  0.25 credits

• 

  RestartResume

  Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

  CME/CE

  Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

  • 

    

    Terry Faleye, MPAS, PA-C

    Peer

  • 

    

    Jonathan I. Silverberg, MD, PhD, MPH

    Peer

  1.00 credits

• 

  RestartResume

  Why We Should Be PRO Patients With CKD-Associated Pruritus

  CME/CE

  Why We Should Be PRO Patients With CKD-Associated Pruritus

  • 

    

    Lucio Manenti, MD, PhD

    Peer

  • 

    

    Jeanette Finderup, PhD, MHR, RN

    Peer

  • 

    

    Sebastian Koball, MD

    Peer

  0.25 credits

• 

  RestartResume

  Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation

  CME/CE

  Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation

  • 

    

    Cara Dolin, MD

    Peer

  • 

    

    Jennifer Simpson

    Peer

  • 

    

    Diana Girnita, MD ,PhD

    Peer

  1.00 credits

• 

  RestartResume

  Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma

  MinuteCE®

  Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  0.75 program credits

• 

  RestartResume

  Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma

  MinuteCE®

  Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma

  • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  0.75 program credits

• 

  RestartResume

  Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  MinuteCE®

  Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  0.75 program credits

• 

  RestartResume

  Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  MinuteCE®

  Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  0.75 program credits

• 

  MinuteCE®

  Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma

  • 

    

    Omid Hamid, MD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  0.75 credits 4 episodes

• 

  RestartResume

  Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

  MinuteCE®

  Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Omid Hamid, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma

  MinuteCE®

  Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma

  • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Ryan Sullivan, MD

    Peer

  • 

    

    Omid Hamid, MD

    Peer

  0.75 program credits

• 1
• 2
• Next